A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

2019397 citationsJournal Articlebronze Open Access

Authors

Andrew Nunn · International Union Against Tuberculosis and Lung Disease

Patrick Phillips · International Union Against Tuberculosis and Lung Disease

Sarah Meredith · International Union Against Tuberculosis and Lung Disease

Chen‐Yuan Chiang · International Union Against Tuberculosis and Lung Disease

Francesca Conradie · University of the Witwatersrand

D. Dalai · National Center for Communicable Diseases

Abstract

In persons with rifampin-resistant tuberculosis that was susceptible to fluoroquinolones and aminoglycosides, a short regimen was noninferior to a long regimen with respect to the primary efficacy outcome and was similar to the long regimen in terms of safety. (Funded by the U.S. Agency for International Development and others; Current Controlled Trials number, ISRCTN78372190; ClinicalTrials.gov number, NCT02409290.).

Topics & Keywords

Tuberculosis Research and Epidemiology Infectious Encephalopathies and Encephalitis Neonatal and fetal brain pathology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 13, pp. 1201-1213

DOI: 10.1056/nejmoa1811867

Field-Weighted Citation Impact: 35.02